Critical Conversations: TIL Webinar Series
HOPA's Collaboration with the Oncology Nursing Society (ONS) Continues with Webinar #3 on TIL Therapy
Filling the Gap in Professional Knowledge Sharing
In mid-February 2024, the Food and Drug Administration approved the world's first ever tumor-infiltrating lymphocyte (TIL) therapy for people with advanced melanoma. Along with its success comes a fast-growing demand for patient access and the development of new TIL therapy sites. Currently, there are gaps in providing TIL therapy. There are also gaps in professional knowledge-sharing.
This collaboration between HOPA and ONS is an effort to demonstrate how two organizations can learn together to better understand the logistics of bringing TIL therapy to patients who might benefit from this treatment.
Three Webinars with Three Insights to TIL Therapy
These webinars will offer "behind the scenes" views to TIL therapy. Each webinar will be curated with different content, presented by HOPA and ONS members who will offer their unique vantage points.
Each webinar is 60 minutes in length.
Register for Webinar #3 here
Note: Upon registering, click on the course in your dashboard to obtain your Zoom link.
Registration - offered at no cost - will open for Webinar #3 on Thursday, November 7.
TIL Webinar #3: Essential Steps for Navigating the Tumor-Infiltrating Lymphocyte (TIL) Journey in Melanoma: Common Obstacles, Logistical Considerations, Multidisciplinary Approaches, and Best Practices Throughout the Journey of TIL Therapy
Thursday, December 19 - 1:00-2:00 PM CT, via Zoom
Topic
- TIL Therapy Best Practices
Learning Objectives
- Discuss common obstacles and barriers of onboarding patients for tumor-infiltrating lymphocyte (TIL) therapy
- Evaluate logistical considerations for coordination of care for TIL therapy
- Illustrate multidisciplinary approaches for maintaining the TIL course
- Review supportive care measures and best practices post-TIL infusion
Session Description
Advancements in cancer treatment have led to the first FDA-approved cellular therapy product to treat solid tumors. This tumor-infiltrating lymphocyte (TIL) therapy has been added to the treatment armamentarium for patients with metastatic melanoma at a critical point in their cancer journey. As this exciting treatment option becomes reality, institutions can face many challenges as they attempt to integrate this new therapy into current practices. This panel session will explore the TIL journey from initial evaluation through hospitalization and supportive care. We will discuss common obstacles, logistical considerations, multidisciplinary approaches, and best practices associated with the TIL process.
There will be 1.0 CE credit and 1.0 NCPD credit available for Webinar #3.
Click here to register for Webinar #3
Meet Our Moderator
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Dr. Mahmoudjafari is a Clinical Pharmacy Manager at the University of Kansas Health System in Kansas City, Kansas.
She has presented nationally on her experience with managing high-cost therapies, and on clinical topics such as CAR T-cell therapies, acute and chronic graft versus host disease, and the management of fungal infections in hematopoietic stem cell transplantation.
Her expert knowledge and friendly presentation style makes her an excellent choice to moderate this series!
Meet Our Speakers
Andrea Fadel, RN, BSN, BMTCN, OCN
Andrea Fadel is a Transplant and Cellular Therapy Nurse Coordinator at University of Chicago Medicine. She has experience working with stem cell transplant and cellular therapy products including CAR-T, TILs, TCR, and NK cells covering both investigational and commercial products.
Rebecca Gonzalez, PharmD, BCOP
Dr. Rebecca Gonzalez is a Board Certified in Oncology Pharmacist and currently practices as a Clinical Pharmacist Specialist in Blood and Marrow Transplant/Cellular Immunotherapy at Moffitt in Tampa, Florida.
Eugene Przespolewski, PharmD, BCOP, DPLA
Dr. Eugene Przespolewski currently serves as Clinical Pharmacist Specialist at Roswell Park Comprehensive Cancer Center in Buffalo, NY serving patients afflicted with Lymphoma, Leukemia and Multiple Myeloma.
Lauren Walford, RN, BSN, BMTCN
Lauren Walford is a case management nurse at Nebraska Medicine specializing in BMT/CAR T and cellular therapy. Continuing her passion for oncology, she now coordinates patients through a variety of therapies including BMT, CAR T, gene therapy, and TIL therapy.
